Abbiati G A, Bertin D, Ibba M, Graziani G, Testa R
Arch Int Pharmacodyn Ther. 1986 Mar;280(1):117-28.
The relationship between plasma, brain and cerebellum concentrations of Denzimol a new anticonvulsant agent, and its anticonvulsant and neurotoxic effects were studied in the rat. Sixty minutes after oral administration, a high brain/plasma concentration ratio of 10:1 was found. Mean plasma, brain and cerebellum half-lives of the drug were 8.4, 7.1 and 9.2 hr, respectively. The anticonvulsant activity of the drug was examined by maximal electroshok seizures (MES). Neurotoxicity was determined both by the rotarod performance test and by behavioural observation. Denzimol was effective against MES, in the ranges of 0.8-5 micrograms/ml and 10-50 micrograms/ml for plasma and brain concentrations, respectively, without causing clear signs of neurological toxicity. It is concluded that the anticonvulsant and neurotoxic effects of denzimol are correlated to its plasma and brain concentrations.
在大鼠身上研究了新型抗惊厥药登齐莫尔的血浆、脑和小脑浓度与其抗惊厥作用及神经毒性效应之间的关系。口服给药60分钟后,发现脑/血浆浓度比高达10:1。该药物的血浆、脑和小脑平均半衰期分别为8.4小时、7.1小时和9.2小时。通过最大电休克惊厥(MES)试验检测该药物的抗惊厥活性。通过转棒试验和行为观察来确定神经毒性。登齐莫尔对MES有效,血浆浓度在0.8 - 5微克/毫升范围内,脑浓度在10 - 50微克/毫升范围内,且未引起明显的神经毒性迹象。得出的结论是,登齐莫尔的抗惊厥作用和神经毒性效应与其血浆和脑浓度相关。